The FDA has granted accelerated approval to Avmapki (avutometinib) plus Fakzynja (defactinib) for the treatment of KRAS-mutated, recurrent low-grade serous ovarian cancer.

The Trump administration has terminated National Institutes of Health (NIH) grants totaling more than $1.8 billion, and the National Cancer Institute (NCI) is among the top 5 institutes with the most ...